# Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX

> **NCT03754790** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Genzyme, a Sanofi Company** · enrollment: 281 (actual)

## Conditions studied

- Hemophilia

## Interventions

- **DRUG:** Fitusiran

## Key facts

- **NCT ID:** NCT03754790
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-01-09
- **Primary completion:** 2026-11-05
- **Final completion:** 2026-11-05
- **Target enrollment:** 281 (ACTUAL)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03754790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03754790, "Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03754790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*